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Open accAbstract The incidence and mortality of breast cancer continues to rise rapidly in Asian
countries. However, most of our current knowledge on breast cancer has been generated in
Western populations. As the socio-economic proﬁle, life style and culture of Asian and Wes-
tern women are substantially different, and genetic backgrounds vary to some extent, we need
to answer the question on whether to ‘adopt’ or ‘adapt’ Western knowledge before applying it
in the Asian setting.
It is generally accepted that breast cancer risk factors, which have mainly been studied in
Western populations are similar worldwide. However, the presence of gene–environment or
gene–gene interactions may alter their importance as causal factors across populations. Diag-
nostic and prognostic study ﬁndings, including breast cancer prediction rules, are increasingly
shown to be ‘setting speciﬁc’ and must therefore be validated in Asian women before imple-
menting them in clinical care in Asia. Interventional research ﬁndings from Caucasian patients
may not be applicable in patients in Asia due to differences in tumour biology/proﬁles, metab-
olism of drugs and also health beliefs which can inﬂuence treatment acceptance and adherence.
While breast cancer research in Asia is warranted in all domains of medical research, it is felt
that for Asian breast cancer patients, needs are highest for diagnostic and prognostic studies.
International clinical trials meanwhile need to include breast cancer patients from various Asian
settings to provide an insight into the effectiveness of new treatmentmodalities in this part of the
world.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.14
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In the past few decades, Asia has seen rapid economic
growth resulting in increasing life expectancy, declining
mortality from communicable diseases and westernisa-
tion of lifestyle.1 While these developments are overall
beneﬁcial, they come with a price. Breast cancer inci-
dence is rapidly increasing in Asian populations. In
China and India, incidence rates have increased by up
to 30% over the last 10 years, whereas in Japan, Korea
and Singapore, the rates have doubled or even tripled
in the past few decades.2 The age-standardised incidence
of breast cancer in Singapore, for instance, had
increased from 20.2 per 100,000/year between 1968
and 1972,3 to 60.7 per 100,000/year between 2006 and
2010,4 where much of this is attributed to the decline
in parity and delayed ﬁrst childbirth in Singaporean
women.5 While the incidence of breast cancer in Asian
women is currently still lower than in their Western
counterparts across all age groups (Fig. 1),6 the dramatic
increase of incidence rates in Asian populations renders
it conceivable that in the near future, the majority of
breast cancer patients worldwide will be of Asian
ethnicity.
Most of our current knowledge on breast cancer has
been generated from studies conducted in Western pop-
ulations. Hence, diagnostic and treatment guidelines in
Asia are largely based on Western knowledge. For
instance, the recent consensus guideline on the manage-
ment of HER2-positive breast cancer in Asia was based
only on studies conducted in non-Asian populations.7Fig. 1. Age-speciﬁc breast cancer incidence rates in selected cancer registrie
International Agency for Research on Cancer).The question is whether we can simply adopt current
Western knowledge in Asia, whether we have to adapt
it before implementation, or whether we need new evi-
dence. Central to this issue is that Asian women are sub-
stantially diﬀerent from Western women from many
perspectives, including genetic background, socio-eco-
nomic proﬁle, lifestyle, culture and health beliefs, all of
which play an important role in breast cancer incidence
and prognosis.8 Below, we use some research examples
to support our views on which areas require adopted,
adapted or de novo Asian breast cancer research.
2. Aetiological breast cancer research
While it is generally accepted that the aetiology of
breast cancer is similar worldwide, diﬀerences in
genetic make-up of Asian women may cause diﬀerent
interactions with environmental exposures (e.g. repro-
ductive, dietary), altering their susceptibility to the
beneﬁcial or harmful eﬀects of these exposures. A
meta-analysis investigating the association between
soy intake and breast cancer risk had shown that
the protective eﬀect of soy was observed only in
women of Asian ethnicity (Asian or Asian Ameri-
cans), whereas soy intake was unrelated to breast can-
cer risk in Western women.9 A nested case control
study within the Singapore Chinese Health Study
cohort revealed that the protective eﬀect of dietary
soy isoﬂavones on postmenopausal breast cancer was
restricted to women who were homozygous for the
high activity murine double minute 2 (MDM2) alleles. Source: Bray et al.6 (Reproduced with permission from Freddie Bray,
N. Bhoo-Pathy et al. / European Journal of Cancer 49 (2013) 703–709 705(GG genotype).10 Interestingly, it has been previously
demonstrated that genetic polymorphisms of MDM2
is a risk factor for breast cancer in Chinese women
but not in non-Chinese women.11
Furthermore, the exposure levels or prevalence of
established aetiological factors may be diﬀerent in Asia.
Hence, the relevance or (population) attributable risks
of certain risk factors may substantially diﬀer between
the Western and Asian populations. For instance, alco-
hol consumption and hormone replacement therapy
(HRT) intake have been consistently shown to increase
breast cancer risk in Caucasian women.12–14 In Asia,
the prevalence of alcohol consumption and use of
HRT15 is low and these factors will thus only make a
small contribution to breast cancer incidence. Similarly,
the importance of genetic risk factors depends not only
on the actual relative risk of breast cancer conferred by
the marker but also on its allele frequency which is
known to vary across population.16 A study assessing
13 single nucleotide polymorphisms associated with
breast cancer risk in European populations showed that
these genetic markers confer diﬀerent population risks in
Chinese, Malay and Indian populations due to varia-
tions in the frequency of the risk alleles.17
There are diﬀerences in exposure levels of breast can-
cer risk factors and in breast cancer speciﬁc genetic sus-
ceptibilities between Asian and Western women. New
Asian aetiologic studies should adopt current knowledge
and aim at ﬁnding new causes of breast cancer, some of
which may be speciﬁc for Asian women.3. Diagnostic breast cancer research
A large proportion of breast cancer patients in Asia
present with advanced stages, and up to 25% percent
have distant metastases at initial presentation.18 There
have been demands for the introduction of population
based mass screening mammography in Asian women
over the recent years.19 However, there is little evidence
that breast cancer screening via mammography would
be eﬀective in the Asian setting.20 In addition to cultural,
economic and logistic barriers,21 which are thought to
be the reasons for the low participation rates in Asian
countries with screening programmes (i.e. Hong Kong,
Singapore),19,20 there may be additional problems with
mammography as a screening tool. Approximately
50% of Asian women are diagnosed with breast cancer
before the age of 50 years,22 suggesting that age limits
may need to be adapted. However, the diagnostic per-
formance of mammography is poor in women under
the age of 50 years.23 Moreover, Asian women generally
have small-volume breasts and relatively dense paren-
chymal breast tissue which may obscure detection of
early and small breast tumours.24 In addition, the posi-
tive predictive value of screening mammography is cur-
rently expected to be a lot lower in Asia than in the Westsince the incidence of breast cancer among Asian women
is still relatively lower than their Western counterparts.
Therefore, the implementation of population based
screening mammography in Asia has been considered
by some as misappropriation of resources, even in high
income Asian settings.19
In low and middle income Asian countries, it seems
wise to channel available resources to improve breast
cancer awareness and encourage women with breast
lumps or symptoms to seek treatment.25 In these set-
tings, clinical breast examination (CBE) has been pro-
posed to improve breast cancer detection in treatable
stages. For instance, in East Malaysia, the proportion
of patients presenting with stage III and stage IV breast
cancer was substantially reduced following execution of
a training programme for nurses from rural districts in
the state of Sarawak between1994 and 1999.26 However,
there seems to be a knowledge gap on whether CBE is
eﬀective in reducing mortality from breast cancer in
Asian patients.27 This is currently being addressed by
a large scale randomised trial involving approximately
150,000 women living within the slums of Mumbai,
India which aims to determine the eﬃcacy and cost-
eﬀectiveness of CBE as a screening method to reduce
breast cancer mortality in limited resource settings.28
Furthermore, diagnostic breast cancer research in
Asian settings is extremely scarce. As this type of
research is setting speciﬁc,29 this is probably the domain
that really requires not adoption but either adaption or
new research questions.4. Prognostic breast cancer research
Accurate prognostication of breast cancer is crucial
as it ensures accurate information for patients, and
allows for adequate treatment decisions and risk stratiﬁ-
cation. Prognostic research ﬁndings from Western coun-
tries are used in Asian breast cancer patients, in order to
predict an individual woman’s disease outcome, which is
based on personal as well as disease characteristics, i.e.
TNM stage, grade and receptor status. Microarray gene
expression based prognostic tests for breast cancer such
as Oncotype-Dx30 and Mammaprint31 are steadily
gaining popularity in Western oncology practice settings
as tools in risk stratiﬁcation, and selection and optimisa-
tion of drug regimens for women with early breast can-
cer.32 However, in most Asian settings, the above assays
are not only economically unfeasible, but their clinical
utility remains both unclear, given the higher incidence
of oestrogen receptor negative breast cancers22,33 where
gene arrays have limited added value, and unproven,
given the absence of validation in Asian patients.
Since multigene assays are not feasible in most of
Asia, web-based prognostication tools such as Adju-
vant! Online may be valuable in clinical practice. Adju-
vant! Online which was developed in the United States
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End Results registry,34 is also widely used in Europe35,36
and Asia37 as a tool to aid patient counselling and clin-
ical decision making in the management of women with
early breast cancer following receipt of loco-regional
treatment. However, a recent study conducted in a mul-
tiethnic Asian setting found that Adjuvant! Online sig-
niﬁcantly overestimated survival in Asian breast cancer
patients especially in women aged less than 40 years,
as well as in patients of Malay ethnicity.38 This study
underscores the need to validate Western derived prog-
nostic models in Asian patients, and adapting them to
improve their predictive capacity. It may even be neces-
sary to build new ‘Asia-speciﬁc’ prediction models using
a large cohort of Asian breast cancer patients.5. Intervention research in breast cancer
Interventions and treatments that are developed and
shown to be eﬀective in Caucasian populations may
not necessarily be eﬀective in Asian women. There are
several reasons why ﬁndings from clinical intervention
trials conducted in Western settings may not apply to
Asian populations. The metabolism of anticancer drugs
for instance may diﬀer between individuals due to pres-
ence of underlying genetic variations.39 A recent review
looking at diﬀerences in toxicity and clinical outcome
following treatment with anticancer drugs highlighted
that there may be ethnic diﬀerences in tolerability and
response to hormonal treatment and cytotoxic chemo-
therapy in breast cancer suggesting that anti-cancer
drugs may be more eﬀective in certain ethnic groups.40
The presence of underlying pharmacogenomic diﬀer-
ences in drug metabolism and response,41,42 may also
lead to diﬀerential tolerance to chemotherapy with
higher occurrences of acute toxicities to chemotherapy.
In addition, body mass index is also inversely associated
with chemotherapy related toxicities.43 In a multicentre
international study, Asian breast cancer patients were
shown to be signiﬁcantly more likely to experience grade
3 haematologic toxicities from FEC 100 chemotherapy
than their Caucasian, African American and Hispanic
counterparts.43 This was however, fully explained by
the fact that the Asian patients were signiﬁcantly less
likely to be overweight or obese compared to the non-
Asians in this study.
Based on the above factors, it is conceivable that the
dose intensity/density in Asian patients may be compro-
mised due to lower tolerance to chemotherapy, leading
to administration of lower doses of chemotherapy than
the recommended dose e.g. the FEC 75 regime.38
Anticancer drugs therefore need to be evaluated in
multiethnic Asian populations before claims on the
potential beneﬁts of the new treatment can be made.
The Korea Food and Drug Administration for instance
pay considerable importance to ethnic equivalence indrug safety and eﬃcacy data generated in Western
populations.44 In China, the State Food and Drug
Administration requires that local pharmacokinetic
studies are conducted in Chinese patients, and a mini-
mum of 100 Chinese patients per intervention arm are
included in international Phase III trials, before a new
drug gets approval for marketing in China.44
As only ﬁve percent of global spending on cancer is in
developing countries, most current strategies for breast
cancer treatment in aﬄuent Western countries are not
applicable in a major part of Asia.45 Poor compliance
to (expensive) cancer treatment due to social, ﬁnancial
and cultural factors may also hamper breast cancer out-
comes and needs to be taken into account when translat-
ing the treatment impact of a particular intervention in
Asian patients.46
It is felt that large scale international clinical trials
must include a suﬃcient number of breast cancer
patients from diﬀerent Asian settings to enable appro-
priate conclusions to be made on the eﬀectiveness of
new anticancer therapies in Asians. In instances where
recruiting a large number of Asian patients are not fea-
sible, meta-analyses of large trials should include Asian-
speciﬁc analyses.6. Need for breast cancer research in Asia
While breast cancer mortality has decreased in
many European and North American countries,47
mortality rates continue to rise in many Asian coun-
tries48 resulting in discrepancies in the ratio of breast
cancer mortality versus the incidence, between the
Western and Asian settings. Experts have warned that
most of the developing nations are ill prepared as they
do not have the infrastructure in place to prevent can-
cer, diagnose the disease in an early stage or provide
long-term treatment.49
While some international expert groups such as the
Breast Health Global Initiative50 and CanTreat Interna-
tional49 have been lobbying to improve cancer preven-
tion and control in developing countries, Asian
governments also need to proactively take actions to
combat cancer. Breast cancer should not be regarded
as ‘low priority’ to merit the allocation of precious
health care dollars.8,51 This would otherwise lead to a
vicious cycle where deﬁcient funding leads to inadequate
infra-structure with inaccessible cancer diagnostic and
therapeutic facilities, lack of manpower (e.g. oncolo-
gists, pathologists and epidemiologists) and lack of reli-
able cancer registration. What is striking in Asia is that
less than one in three countries collect data on cancer
incidence, and only one in six countries monitor cancer
mortality.49 This in return makes knowledge on breast
cancer reprehensibly scarce, and causes diﬃculties in
objectively ascertaining the magnitude of the problem
in Asia. Cancer registration is therefore vital and what
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include adequate professional staﬃng, sustainable fund-
ing and continuous support from the medical commu-
nity as well as the policy makers.52
In Asian countries where there is an absence of reli-
able population based cancer registries, predicting rises
of breast cancer incidence based on changes in simple
parameters such as total fertility rate and age at ﬁrst
childbirth is not only useful for planning capacity, but
may also stimulate the development of high quality can-
cer registries. In these settings, study ﬁndings from well
conducted hospital based registries will additionally pro-
vide valuable knowledge and insight to aid health care
professionals and policy makers, in making strategic
plans and taking aﬃrmative actions to improve breast
cancer outcomes.
7. Asian breast cancer patients living in the Western
settings
As a result of international migration, an increasing
proportion of Asian women are living in Western set-
tings for instance in the United States, United King-
dom, Australia and Western Europe. The incidence
of breast cancer among Asian women who migrate
to these settings have been reported to escalate with
time, approximating the rates of Caucasian women,
as they gradually undergo acculturation and adopt a
Westernised lifestyle.53,54 This phenomenon ﬁrmly sup-
ports the contribution of environmental and non-
genetic factors in breast carcinogenesis. Some recent
evidence show that women of Asian descent who were
born in Western settings, may in fact experience a
higher risk of breast cancer than Caucasians,55,56 sug-
gesting additional gene–environment interplay. A
recent population based study in California high-
lighted that the Korean, Vietnamese and Chinese
women had substantially higher incidence of HER2-
positive breast cancers compared to the non-Hispanic
whites. The incidence of triple negative breast cancers
meanwhile was signiﬁcantly lower in the Chinese and
Filipino women compared to the non-Hispanic
whites.57 A number of studies have also found that
breast cancer screening participation rate is less than
optimal among Asian women living in the United
States,58 United Kingdom,59 and Australia.60 Interest-
ingly, it has been shown that breast cancer survival in
Asian women living in Western countries is higher
than that of women of other ethnicities, both in the
United Kingdom61 and United States.62 These ﬁndings
serve to highlight that further research is required in
Asian breast cancer patients, as their diﬀerences in
genetic make-up, health beliefs and behaviours and
tumour biology compared to Caucasian women, seem
to substantially impact their risk, as well as outcome
of breast cancer.8. Conclusion
While breast cancer research in Asia is warranted in
all domains of medical research, it is felt that for Asian
breast cancer patients, needs are highest for diagnostic
and prognostic studies. International clinical trials
meanwhile need to include breast cancer patients from
various Asian settings to provide an insight into the
eﬀectiveness of new treatment modalities in this part
of the world.
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